PROLINE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
115.0 -0.2 2 2 49.0 1 0.8
UNII
9DLQ4CIU6V
CAS
147-85-3
SYNONYMS
  • Proline
  • L-Proline
  • L-2-Pyrrolidinecarboxylic Acid
  • Fema No. 3319
  • Proline [inn]
  • Proline [usan]
  • Proline [usp]
  • Proline [ep]
  • L-Proline [jan]
  • Proline [mart.]
  • Proline [mi]
  • Proline [inci]
  • L-Proline [fcc]
  • L-Proline [fhfi]
  • Proline [ii]
  • Proline [hsdb]
  • L-Proline [usp-Rs]
  • Proline [who-Dd]
  • Proline [vandf]
  • Nsc-46703
ZINC ID(s)
Availability
Present in 94 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02370329 2015-03-01 P1101 in Treating Patients With Early Myelofibrosis Phase 2 Not Yet Recruiting
NCT02218047 2014-11-01 AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Phase 3 Recruiting

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Iv(infusion) Injection 80%
Iv(infusion) Solution, Injection 0.34%

More Information

Usage Over Time

Comments